Generate Biomedicines, Inc.(GENB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GENB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Generate Biomedicines, Inc. (GENB), a Healthcare sector company. GENB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Generate Biomedicines, Inc. reports quarterly revenue of $7.2M, net income of $-61.4M, free cash flow of $-84.2M. Top institutional holders of GENB by reported 13-F value include Flagship Pioneering, FMR, Capital World Investors, based on the most recent SEC filings. GENB trades on the Nasdaq exchange and files with the SEC under CIK 2100782. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GENB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generate Biomedicines, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$7.2M
Net Income
Q1 2026
$-61.4M
Free Cash Flow
Q1 2026
$-84.2M
ROIC
Q1 2026
-12.4%
AI Insight: GENB Financial Trends
Single quarter data shows $7M revenue with significant operating losses and negative cash flow of $80M.
• Revenue of $7M in Q1 2026 with operating loss of $64M indicates early-stage operations.
• Operating cash flow negative at $80M reflecting high cash burn rate.
⚠ High burn rate of $80M quarterly against $515M equity base requires monitoring.
AI Insight: GENB Ratio Trends
Single quarter of data shows substantial losses with negative returns across all profitability metrics.
• ROE of -47.7% in Q1 2026 indicates significant shareholder equity destruction from operating losses.
• ROIC of -49.8% reflects poor capital efficiency and substantial cash burn relative to invested capital.
⚠ Need multiple quarters to establish meaningful trends given limited single-quarter dataset.
Get alerted when GENB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Generate Biomedicines, Inc. including:
Top Institutional Holders of GENB
Flagship Pioneering Inc.
$783.4M62,673,117 shFMR LLC
$52.7M4,217,524 shCapital World Investors
$50.1M4,004,149 shBRAIDWELL LP
$44.9M3,592,999 shARCH Venture Management, LLC
$24.3M1,944,426 shHARBOURVEST PARTNERS LLC
$21.5M1,722,210 shBAKER BROS. ADVISORS LP
$17.8M1,423,602 shHARVARD MANAGEMENT CO INC
$13.9M1,111,100 shNVIDIA CORP
$10.4M833,325 shSiren, L.L.C.
$9.2M736,104 sh
| Fund | Value | Shares |
|---|---|---|
| Flagship Pioneering Inc. | $783.4M | 62,673,117 |
| FMR LLC | $52.7M | 4,217,524 |
| Capital World Investors | $50.1M | 4,004,149 |
| BRAIDWELL LP | $44.9M | 3,592,999 |
| ARCH Venture Management, LLC | $24.3M | 1,944,426 |
| HARBOURVEST PARTNERS LLC | $21.5M | 1,722,210 |
| BAKER BROS. ADVISORS LP | $17.8M | 1,423,602 |
| HARVARD MANAGEMENT CO INC | $13.9M | 1,111,100 |
| NVIDIA CORP | $10.4M | 833,325 |
| Siren, L.L.C. | $9.2M | 736,104 |
More Healthcare Companies
View all Healthcare →Put GENB on your watchlist
Track score changes the day Generate Biomedicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GENB a good stock to buy?
13F Pro's AI-powered analysis of Generate Biomedicines, Inc. (GENB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GENB are available on the GENB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GENB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GENB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Generate Biomedicines, Inc.'s investment landscape.